Abstract
Background
Elevated plasma homocysteine and amyloid β (Aβ) have been associated with Alzheimer’s disease (AD). We investigated the cross-sectional association between these biomarkers.
Methods
We used linear regression to relate plasma homocysteine and Aβ adjusting for age, gender, creatinine, APOE-ε4, and ethnic group in 327 persons aged 78 ± 6.6 years.
Results
Plasma homocysteine correlated with age, serum creatinine, plasma Aβ40 and Aβ42, and was inversely correlated with serum vitamin B12, and folate. Aβ42, but not Aβ40, was related to later development of dementia. Homocysteine was related to higher Aβ40 levels (coefficient = 2.0; P < 0.0001) and this association was attenuated after adjustment for creatinine (coefficient = 1.0; P < 0.0001). The crude association between homocysteine and Aβ42 was weaker (coefficient = 0.5; P = 0.01) and became non-significant after adjustment for creatinine (coefficient = 0.4; P = 0.06). These associations were unrelated to ethnicity, the presence of APOE-ε4 or dementia. Analyses by quartiles of homocysteine showed that these association were driven primarily by the fourth quartile.
Conclusions
Plasma homocysteine is directly related to Aβ40. The association with Aβ42 is not significant. These results seem to indicate that homocysteine is related to aging but not specifically to AD.
Similar content being viewed by others
References
Seshadri S, Beiser A, Selhub J et al (2002) Plasma homocysteine as a risk factor for dementia and Alzheimer’s disease. N Engl J Med 346:476–483
Luchsinger JA, Tang M-X, Shea S, Miller J, Green R, Mayeux R (2004) Plasma homocysteine levels and risk of Alzheimer disease. Neurology 62:1972–1976
Budge MM, de Jager C, Hogervorst E, Smith AD, Oxford Project To Investigate Memory and Ageing (2002) Total plasma homocysteine, age, systolic blood pressure, and cognitive performance in older people. J Am Geriatr Soc 50:2014–2018
Miller JW, Green R, Mungas DM, Reed BR, Jagust WJ (2002) Homocysteine, vitamin B6, and vascular disease in AD patients. Neurology.58:1471–1475
Seshadri S, Wolf PA (2003) Homocysteine and the brain: vascular risk factor or neurotoxin? Lancet Neurol 2:11
Ritchie K, Lovestone S (2002) The dementias. Lancet 360:1759–1766
Petersen RC, Doody R, Kurz A et al (2001) Current concepts in mild cognitive impairment. Arch Neurol 58:1985–1992
Cummings JL (2004) Alzheimer’s disease. N Engl J Med 351:56–67
Selkoe DJ (2000) The origins of Alzheimer disease: a is for amyloid. JAMA 283:1615–1617
Frank RA, Galasko D, Hampel H et al (2003) Biological markers for therapeutic trials in Alzheimer’s disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer’s disease. Neurobiol Aging 24:521–536
Schupf N, Patel B, Silverman W et al (2001) Elevated plasma amyloid beta-peptide 1–42 and onset of dementia in adults with Down syndrome. Neurosci Lett 301:199–203
Scheuner D, Eckman C, Jensen M et al (1996) Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer’s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer’s disease. Nat Med 2:864–870
Mayeux R, Tang MX, Jacobs DM et al (1999) Plasma amyloid beta-peptide 1–42 and incipient Alzheimer’s disease. Ann Neurol 46:412–416
Mayeux R, Honig LS, Tang M-X et al (2003) Plasma A{beta}40 and A{beta}42 and Alzheimer’s disease: relation to age, mortality, and risk. Neurology 61:1185–1190
Assini A, Cammarata S, Vitali A et al (2004) Plasma levels of amyloid {beta}-protein 42 are increased in women with mild cognitive impairment. Neurology 63:828–831
Tang MX, Stern Y, Marder K et al (1998) The APOE-epsilon4 allele and the risk of Alzheimer disease among African Americans, whites, and Hispanics. JAMA 279:751–755
Stern Y, Andrews H, Pittman J et al (1992) Diagnosis of dementia in a heterogeneous population. development of a neuropsychological paradigm-based diagnosis of dementia and quantified correction for the effects of education. Arch Neurol 49:453–460
Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) (1994) American Psychiatric Association, Washington, DC, pp 143–147
Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL (1982) A new clinical scale for the staging of dementia. Br J Psychiatry 140:566–572
McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s disease. Neurology 34:939–944
Honig LS, Tang MX, Albert S et al (2003) Stroke and the risk of Alzheimer disease. Arch Neurol 60:1707–1712
Mayeux R, Honig LS, Tang MX et al (2003) Plasma A[beta]40 and A[beta]42 and Alzheimer’s disease: relation to age, mortality, and risk. Neurology 61:1185–1190
Luchsinger JA, Tang MX, Shea S, Miller J, Green R, Mayeux R (2004) Plasma homocysteine levels and risk of Alzheimer disease. Neurology 62:1972–1976
Gilfix BM, Blank DW, Rosenblatt DS (1997) Novel reductant for determination of total plasma homocysteine. Clin Chem 43:687–688
Fleiss JL (1981) Statistical methods for rates and proportions, 2nd edn. Joseph Wiley and Sons
Hofman A, Ott A, Breteler MM et al (1997) Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer’s disease in the Rotterdam study. Lancet 349:151–154
Luchsinger J, Mayeux R (2004) Cardiovascular risk factors and Alzheimer’s disease. Curr Atheroscler Rep 6:261–266
Aisen PS, Egelko S, Andrews H et al (2003) A pilot study of vitamins to lower plasma homocysteine levels in Alzheimer disease. Am J Geriatr Psychiatry 11:246–249
McIlroy SP, Dynan KB, Lawson JT, Patterson CC, Passmore AP (2002) Moderately elevated plasma homocysteine, methylenetetrahydrofolate reductase genotype, and risk for stroke, vascular dementia, and Alzheimer disease in Northern Ireland. Stroke 33:2351–2356
McCaddon A, Hudson P, Davies G, Hughes A, Williams JH, Wilkinson C (2001) Homocysteine and cognitive decline in healthy elderly. Dement Geriatr Cogn Disord 12:309–313
Prins ND, Den Heijer T, Hofman A et al (2002) Homocysteine and cognitive function in the elderly: the Rotterdam scan study. Neurology 59:1375–1380
Sachdev PS, Valenzuela MJ, Brodaty H et al (2003) Homocysteine as a risk factor for cognitive impairment in stroke patients. Dement Geriatr Cogn Disord 15:155–162
den Heijer T, Vermeer SE, Clarke R et al (2003) Homocysteine and brain atrophy on MRI of non-demented elderly. Brain 126:170–175
Bostom AG, Rosenberg IH, Silbershatz H et al (1999) Nonfasting plasma total homocysteine levels and stroke incidence in elderly persons: the Framingham study. Ann Intern Med 131:352–355
Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shaper AG (1995) Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet 346:1395–1398
Vermeer SE, van Dijk EJ, Koudstaal PJ et al (2002) Homocysteine, silent brain infarcts, and white matter lesions: the Rotterdam scan study. Ann Neurol 51:285–289
Honig LS, Tang MX, Albert S et al (2003) Stroke and the risk of Alzheimer disease. Arch Neurol 60:1707–1712
Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MM (2003) Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 348:1215–1222
He K, Merchant A, Rimm EB et al (2004) Folate, vitamin B6, and B12 intakes in relation to risk of stroke among men. Stroke 35:169–174
Toole JF, Malinow MR, Chambless LE et al (2004) Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: The Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 291:565–575
Ho PI, Collins SC, Dhitavat S et al (2001) Homocysteine potentiates beta-amyloid neurotoxicity: role of oxidative stress. J Neurochem 78:249–253
Mok SS, Turner BJ, Beyreuther K, Masters CL, Barrow CJ, Small DH (2002) Toxicity of substrate-bound amyloid peptides on vascular smooth muscle cells is enhanced by homocysteine. Eur J Biochem 269:3014–3022
Kruman II, Culmsee C, Chan SL et al (2000) Homocysteine elicits a DNA damage response in neurons that promotes apoptosis and hypersensitivity to excitotoxicity. J Neurosci 20:6920–6926
Kruman II, Kumaravel TS, Lohani A et al (2002) Folic acid deficiency and homocysteine impair DNA repair in hippocampal neurons and sensitize them to amyloid toxicity in experimental models of Alzheimer’s disease. J Neurosci 22:1752–1762
Selkoe DJ (1997) Alzheimer’s disease: genotypes, phenotypes, and treatments. Science 275:630–631
Pak KJ, Chan SL, Mattson MP (2003) Homocysteine and folate deficiency sensitize oligodendrocytes to the cell death-promoting effects of a presenilin-1 mutation and amyloid beta-peptide. Neuromol Med 3:119–128
Pacheco-Quinto J, Rodriguez de Turco EB, DeRosa S et al (2006) Hyperhomocysteinemic Alzheimer’s mouse model of amyloidosis shows increased brain amyloid [beta] peptide levels. Neurobiol Dis 22:651–656
Irizarry MC, Gurol ME, Raju S et al (2005) Association of homocysteine with plasma amyloid {beta} protein in aging and neurodegenerative disease. Neurology 65:1402–1408
Acknowledgments
Support for this work was provided by grants from the National Institutes of Health AG15294, AG07232, AG07702, AG20856, RR00645 from the Charles S. Robertson Memorial Gift for research on Alzheimer’s disease, and from the Blanchette Hooker Rockefeller Foundation.
Author information
Authors and Affiliations
Corresponding author
Additional information
Special issue dedicated to John P. Blass.
Rights and permissions
About this article
Cite this article
Luchsinger, J.A., Tang, MX., Miller, J. et al. Relation of Plasma Homocysteine to Plasma Amyloid Beta Levels. Neurochem Res 32, 775–781 (2007). https://doi.org/10.1007/s11064-006-9207-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11064-006-9207-7